AR093036A1 - Derivados de pirrolotriazinona como inhibidores de pi3k - Google Patents

Derivados de pirrolotriazinona como inhibidores de pi3k

Info

Publication number
AR093036A1
AR093036A1 ARP130103757A ARP130103757A AR093036A1 AR 093036 A1 AR093036 A1 AR 093036A1 AR P130103757 A ARP130103757 A AR P130103757A AR P130103757 A ARP130103757 A AR P130103757A AR 093036 A1 AR093036 A1 AR 093036A1
Authority
AR
Argentina
Prior art keywords
group
linear
phenyl
heteroatom selected
branched
Prior art date
Application number
ARP130103757A
Other languages
English (en)
Spanish (es)
Inventor
Casals Coll Gaspar
Begoa Hernandez Olasagarre Maria
Mir Cepeda Marta
Miquel Pages Santacana Lluis
Erra Sola Montserrat
Carrascal Riera Marta
Taltavull Moll Joan
Francisco Caturla Javaloyes Juan
Javier Bernal Anchuela Francisco
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR093036A1 publication Critical patent/AR093036A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP130103757A 2012-10-16 2013-10-16 Derivados de pirrolotriazinona como inhibidores de pi3k AR093036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12382399 2012-10-16

Publications (1)

Publication Number Publication Date
AR093036A1 true AR093036A1 (es) 2015-05-13

Family

ID=47049114

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103757A AR093036A1 (es) 2012-10-16 2013-10-16 Derivados de pirrolotriazinona como inhibidores de pi3k

Country Status (29)

Country Link
US (1) US9388189B2 (https=)
EP (1) EP2909207A1 (https=)
JP (1) JP2015533181A (https=)
KR (1) KR20150068953A (https=)
CN (1) CN104854108A (https=)
AP (1) AP2015008328A0 (https=)
AR (1) AR093036A1 (https=)
AU (1) AU2013333938A1 (https=)
BR (1) BR112015007231A2 (https=)
CA (1) CA2883426A1 (https=)
CL (1) CL2015000956A1 (https=)
CR (1) CR20150175A (https=)
DO (1) DOP2015000077A (https=)
EA (1) EA027277B1 (https=)
GE (1) GEP201706623B (https=)
GT (1) GT201500094A (https=)
HK (1) HK1211027A1 (https=)
IL (1) IL237475A0 (https=)
MD (1) MD20150048A2 (https=)
MX (1) MX2015004327A (https=)
NI (1) NI201500054A (https=)
PE (1) PE20150637A1 (https=)
PH (1) PH12015500813A1 (https=)
SG (1) SG11201502032VA (https=)
TN (1) TN2015000112A1 (https=)
TW (1) TW201429975A (https=)
UY (1) UY35086A (https=)
WO (1) WO2014060432A1 (https=)
ZA (1) ZA201501220B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
EP2997030B1 (en) * 2013-05-14 2017-08-09 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
MX2017000208A (es) 2014-07-04 2017-05-01 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
WO2017076990A1 (en) 2015-11-05 2017-05-11 Almirall, S.A. Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3472165B1 (en) * 2016-06-21 2023-09-06 Nerviano Medical Sciences S.r.l. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基-吡咯并嘧啶酮化合物及其用途
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3768698B1 (en) 2018-03-19 2025-02-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2022000443A1 (en) * 2020-07-03 2022-01-06 Nanjing Immunophage Biotech Co., Ltd. Methods and compositions for targeting tregs using ccr8 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6752411B2 (en) 2002-06-24 2004-06-22 Norco Industries, Inc. Multi-stage torsion axle
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
SI2612862T1 (sl) * 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DK200400182U4 (da) 2004-06-23 2005-10-14 Alfa Laval Tank Equipment As Drivenhed især til brug i forbindelse med tankrenseudstyr
GB0417709D0 (en) 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
AU2006283846B2 (en) * 2005-08-26 2012-04-05 Merck Serono Sa Pyrazine derivatives and use as PI3K inhibitors
US7759350B2 (en) 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
US7525866B2 (en) 2006-04-19 2009-04-28 Freescale Semiconductor, Inc. Memory circuit
FI20065449A0 (fi) 2006-06-29 2006-06-29 Nokia Corp Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
ITRN20070034A1 (it) 2007-06-27 2008-12-28 Sica Spa Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza.
TWI441601B (zh) 2007-06-28 2014-06-21 Philip Morris Products Sa 具有高白堊含量之圖案化包裝紙
US20100286145A1 (en) 2007-07-26 2010-11-11 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
BRPI1014253A2 (pt) 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
WO2011058109A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011119704A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
CA2799579A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012000202A1 (zh) 2010-07-02 2012-01-05 Tsai Wen-Kai 人员派遣事务机及其应用的人员派遣方法
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP2699257A4 (en) 2011-04-21 2014-10-15 Univ Louisiana State PEPTIDE AND CONJUGATE VACCINES FOR FUNGI INFECTIONS
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN102229416B (zh) 2011-06-29 2013-06-05 三一汽车起重机械有限公司 一种起重机闭式回转液压系统及起重机
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods

Also Published As

Publication number Publication date
AU2013333938A1 (en) 2015-04-09
NI201500054A (es) 2016-02-01
CL2015000956A1 (es) 2015-06-19
IL237475A0 (en) 2015-04-30
GEP201706623B (en) 2017-02-10
GT201500094A (es) 2017-08-01
TW201429975A (zh) 2014-08-01
EA027277B1 (ru) 2017-07-31
PH12015500813B1 (en) 2015-06-08
SG11201502032VA (en) 2015-05-28
BR112015007231A2 (pt) 2017-07-04
KR20150068953A (ko) 2015-06-22
HK1211027A1 (en) 2016-05-13
UY35086A (es) 2014-05-30
CA2883426A1 (en) 2014-04-24
MX2015004327A (es) 2015-06-10
US9388189B2 (en) 2016-07-12
DOP2015000077A (es) 2015-04-30
WO2014060432A1 (en) 2014-04-24
PE20150637A1 (es) 2015-05-08
PH12015500813A1 (en) 2015-06-08
ZA201501220B (en) 2017-04-26
EP2909207A1 (en) 2015-08-26
JP2015533181A (ja) 2015-11-19
AP2015008328A0 (en) 2015-03-31
US20150291595A1 (en) 2015-10-15
TN2015000112A1 (en) 2016-06-29
EA201500426A1 (ru) 2015-10-30
CR20150175A (es) 2015-05-11
CN104854108A (zh) 2015-08-19
MD20150048A2 (ro) 2015-10-31

Similar Documents

Publication Publication Date Title
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR092742A1 (es) Piridinonas antifibroticas
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR098048A1 (es) Inhibidores de fgfr4
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
AR089285A1 (es) Derivados de betulina
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR106472A1 (es) Inhibidores de acc y usos de los mismos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
PY1411052A (es) Compuestos heterocíclicos y usos de los mismos
AR088760A1 (es) Derivados de pirrolopirimidina y purina
AR092288A1 (es) Ligandos del receptor ep1
AR105991A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
AR094797A1 (es) Derivados de pirrolotriazina como inhibidores de pi3k
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR098723A1 (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
AR096424A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
AR096423A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
AR099867A1 (es) Compuestos imidazobenzotiazolo fusionados

Legal Events

Date Code Title Description
FB Suspension of granting procedure